Table 1.
Clinical characteristics of TNBC patients in the training and validation groups.
| Clinical characteristics | Training group | Validation group | P value |
|---|---|---|---|
| N = 102 | N = 298 | ||
| Age (years, mean ± SD) | 57.01 ± 11.75 | 55.66 ± 13.76 | 3.38E-01 |
| Pathological M (M0/M1/-) | 85/1/16 | NA | NA |
| Pathological N (N0/N1/N2/N3/-) | 65/23/11/3 | NA | NA |
| Pathological T (T1/T2/T3/T4) | 23/64/11/4 | NA | NA |
| Pathologic stage (I/II/III/IV/-) | 16/65/17/1/3 | 62/130/25/0/81 | 2.48E-02 |
| Radiotherapy (Yes/No/-) | 53/40/9 | 214/84 | 1.04E-02 |
| Recurrence (Yes/No/-) | 15/78/9 | NA | NA |
| Death (Yes/No) | 16/86 | 161/137 | 3.50E-12 |
| Overall survival time (months, mean ± SD) | 38.95 ± 31.34 | 113.42 ± 83.37 | 2.62E-12 |
TNBC, triple-negative breast cancer; NA, not applicable. A P value < 0.05 was considered to be statistically significant. The bold values represent statistically significant.